source
- FDA clears Click Therapeutics' Motivista, first digital therapeutic for negative schizophrenia symptomsClick Therapeutics received FDA 510(k) clearance for its digital therapeutic, Motivista (formerly CT-155), marking the first authorized treatment targeting negative symptoms of schizophrenia in the…
- European regulators withdraw Amgen's Tavneos over questionable dataEuropean regulators announced they are pulling Amgen's rare disease drug Tavneos from the European market after reviewing data they deemed incorrect and misleading. The authorities said the data s…